New pill shows promise for Tough-to-Treat lung cancer

NCT ID NCT07231068

Recruiting now Disease control Sponsor: Henan Genuine Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated Apr 28, 2026 · Updated 18 times

Summary

This study tests a new drug called dositinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The goal is to find the safest dose and see if it can shrink tumors. About 153 adults aged 18-75 who have already tried other treatments will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, China
Henan Provincial Cancer Hospital
RECRUITING

Zhengzhou, China
Henan Provincial People's Hospital
RECRUITING

Zhengzhou, China
Peking Union Medical College Hospital
WITHDRAWN

Beijing, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, China

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER